Barinthus Biotherapeutics PLC
NASDAQ:BRNS

Watchlist Manager
Barinthus Biotherapeutics PLC Logo
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Watchlist
Price: 1.24 USD -6.77% Market Closed
Market Cap: 50m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

BRNS Price Targets Summary
Barinthus Biotherapeutics PLC

Wall Street analysts forecast BRNS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BRNS is 4.59 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

BRNS Lowest Forecast
Wall Street Target
3.03 USD
144% Upside
BRNS Average Forecast
Wall Street Target
4.59 USD
270% Upside
BRNS Highest Forecast
Wall Street Target
6.3 USD
408% Upside
Lowest
Price Target
3.03 USD
144% Upside
Average
Price Target
4.59 USD
270% Upside
Highest
Price Target
6.3 USD
408% Upside
Barinthus Biotherapeutics PLC Competitors:
Price Targets
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
7% Downside
IMM
Immutep Ltd
415% Upside
VCEL
Vericel Corp
59% Upside
RYTM
Rhythm Pharmaceuticals Inc
12% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
7% Downside
IMM
Immutep Ltd
415% Upside
VCEL
Vericel Corp
59% Upside
RYTM
Rhythm Pharmaceuticals Inc
12% Upside
HPHA
Heidelberg Pharma AG
294% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
52% Upside
AGIO
Agios Pharmaceuticals Inc
41% Upside
IMTX
Immatics NV
126% Upside

Revenue
Forecast

Revenue Estimate
Barinthus Biotherapeutics PLC

For the last 4 years the compound annual growth rate for Barinthus Biotherapeutics PLC's revenue is 33%.

33%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Barinthus Biotherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Barinthus Biotherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
What are analyst estimates?

See Also

Summary
BRNS intrinsic value, competitors valuation, and company profile.
DCF Valuation
BRNS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BRNS stock valuation using valuation multiples.
Wall Street Estimates
BRNS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BRNS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BRNS's stock price target?
Price Target
4.59 USD

According to Wall Street analysts, the average 1-year price target for BRNS is 4.59 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 280,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.